Temsirolimus (CCI-779) is another intravenous mTOR inhibitor and a prodrug of rapamycin, that binds to the intracellular protein FKBP-12 and leads to cell cycle arrest in G1 phase; it also inhibits tumour angiogenesis by reducing the synthesis of vascular endothelial growth factor (VEGF) [40]. This evidence concerns the gene MTOR and neoplasm.